<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Etr større skriv om MM:]]></title><description><![CDATA[<p dir="auto">Etr større skriv om MM:</p>
<p dir="auto"><a href="http://www.boltinternational.com/wp-content/uploads/2011/06/multiple-myeloma-tlp-26-2011-02-bolt-brochure.pdf" rel="nofollow ugc">http://www.boltinternational.com/wp-content/uploads/2011/06/multiple-myeloma-tlp-26-2011-02-bolt-brochure.pdf</a></p>
<p dir="auto">Elotuzumab (med Revlimid og low-dose dexamethasone) ses at have god effekt på MM relapsed (92% ORR):</p>
<p dir="auto"><a href="http://abstract.asco.org/AbstView_114_92546.html" rel="nofollow ugc">http://abstract.asco.org/AbstView_114_92546.html</a></p>
<p dir="auto">Nu går Elotuzumab efter frontline i to fase 3 forsøg.</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/448425/etr-strre-skriv-om-mm</link><generator>RSS for Node</generator><lastBuildDate>Fri, 19 Jun 2026 14:38:24 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/448425.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 17 May 2012 16:18:27 GMT</pubDate><ttl>60</ttl></channel></rss>